(GETI-B) Getinge ser. - Ratings and Ratios
Ventilator, Sterilizer, Operating Room, ECMO, ICU Equipment
GETI-B EPS (Earnings per Share)
GETI-B Revenue
Description: GETI-B Getinge ser.
Getinge AB ser. B is a Swedish healthcare company that provides a wide range of medical equipment and solutions for hospitals and healthcare facilities worldwide. The companys product portfolio includes equipment for operating rooms, intensive care units, and sterilization departments, such as extracorporeal membrane oxygenation, mechanical ventilation, and advanced patient monitoring.
The companys business is divided into three main segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge AB has a strong presence in the global healthcare market, with a network of sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region.
From a financial perspective, Getinge AB has a market capitalization of approximately 52.3 billion SEK, with a price-to-earnings ratio of 35.46 and a forward P/E of 17.21. The companys return on equity is 4.72%, indicating a relatively modest level of profitability. To further analyze the companys financial health, we can examine additional KPIs such as debt-to-equity ratio, interest coverage ratio, and operating margin.
Some key performance indicators (KPIs) to monitor for Getinge AB include revenue growth, gross margin, and research and development (R&D) expenses as a percentage of sales. The companys ability to innovate and bring new products to market is crucial in the highly competitive healthcare equipment industry. Additionally, metrics such as customer satisfaction, product reliability, and after-sales support are essential in driving customer loyalty and retention.
To evaluate the investment potential of Getinge AB, we can analyze the companys competitive position, market trends, and growth prospects. The global healthcare equipment market is driven by factors such as aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Getinge ABs diversified product portfolio and strong global presence position the company for potential long-term growth.
GETI-B Stock Overview
| Market Cap in USD | 6,205m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception |
GETI-B Stock Ratings
| Growth Rating | 3.96% |
| Fundamental | 63.8% |
| Dividend Rating | 60.7% |
| Return 12m vs S&P 500 | -18.1% |
| Analyst Rating | - |
GETI-B Dividends
| Dividend Yield 12m | 2.28% |
| Yield on Cost 5y | 2.67% |
| Annual Growth 5y | 7.96% |
| Payout Consistency | 94.3% |
| Payout Ratio | 38.5% |
GETI-B Growth Ratios
| Growth Correlation 3m | 90.7% |
| Growth Correlation 12m | 7.4% |
| Growth Correlation 5y | -34.5% |
| CAGR 5y | 7.74% |
| CAGR/Max DD 3y | 0.21 |
| CAGR/Mean DD 3y | 0.40 |
| Sharpe Ratio 12m | -0.14 |
| Alpha | 0.10 |
| Beta | 0.414 |
| Volatility | 28.25% |
| Current Volume | 313.5k |
| Average Volume 20d | 368.2k |
| Stop Loss | 204.9 (-3%) |
| Signal | -0.47 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.49b TTM) > 0 and > 6% of Revenue (6% = 2.13b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -1.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.11% (prev 6.39%; Δ 1.73pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 4.03b > Net Income 1.49b (YES >=105%, WARN >=100%) |
| Net Debt (9.22b) to EBITDA (6.37b) ratio: 1.45 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (272.4m) change vs 12m ago 0.00% (target <= -2.0% for YES) |
| Gross Margin 46.89% (prev 43.94%; Δ 2.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 63.62% (prev 60.34%; Δ 3.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.97 (EBITDA TTM 6.37b / Interest Expense TTM 642.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.80
| (A) 0.05 = (Total Current Assets 15.73b - Total Current Liabilities 12.85b) / Total Assets 56.37b |
| (B) 0.35 = Retained Earnings (Balance) 19.95b / Total Assets 56.37b |
| (C) 0.07 = EBIT TTM 3.83b / Avg Total Assets 55.80b |
| (D) 0.81 = Book Value of Equity 22.03b / Total Liabilities 27.35b |
| Total Rating: 2.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.83
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 4.09% = 2.05 |
| 3. FCF Margin 7.62% = 1.90 |
| 4. Debt/Equity 0.35 = 2.44 |
| 5. Debt/Ebitda 1.59 = 0.80 |
| 6. ROIC - WACC (= 1.98)% = 2.47 |
| 7. RoE 4.86% = 0.41 |
| 8. Rev. Trend 47.96% = 3.60 |
| 9. EPS Trend 3.27% = 0.16 |
What is the price of GETI-B shares?
Over the past week, the price has changed by -0.47%, over one month by +3.27%, over three months by +12.39% and over the past year by -2.81%.
Is Getinge ser. a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GETI-B is around 207.14 SEK . This means that GETI-B is currently overvalued and has a potential downside of -1.97%.
Is GETI-B a buy, sell or hold?
What are the forecasts/targets for the GETI-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 228.1 | 8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 227 | 7.4% |
GETI-B Fundamental Data Overview
Market Cap SEK = 57.88b (57.88b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 1.95b SEK (last quarter)
P/E Trailing = 38.7912
P/E Forward = 15.949
P/S = 1.6305
P/B = 2.0015
P/EG = 0.9114
Beta = 0.846
Revenue TTM = 35.50b SEK
EBIT TTM = 3.83b SEK
EBITDA TTM = 6.37b SEK
Long Term Debt = 7.91b SEK (from longTermDebt, last quarter)
Short Term Debt = 2.19b SEK (from shortTermDebt, last quarter)
Debt = 10.10b SEK (Calculated: Short Term 2.19b + Long Term 7.91b)
Net Debt = 9.22b SEK (from netDebt column, last quarter)
Enterprise Value = 66.04b SEK (57.88b + Debt 10.10b - CCE 1.95b)
Interest Coverage Ratio = 5.97 (Ebit TTM 3.83b / Interest Expense TTM 642.0m)
FCF Yield = 4.09% (FCF TTM 2.70b / Enterprise Value 66.04b)
FCF Margin = 7.62% (FCF TTM 2.70b / Revenue TTM 35.50b)
Net Margin = 4.20% (Net Income TTM 1.49b / Revenue TTM 35.50b)
Gross Margin = 46.89% ((Revenue TTM 35.50b - Cost of Revenue TTM 18.85b) / Revenue TTM)
Tobins Q-Ratio = 3.00 (Enterprise Value 66.04b / Book Value Of Equity 22.03b)
Interest Expense / Debt = 1.45% (Interest Expense 147.0m / Debt 10.10b)
Taxrate = 27.52% (628.0m / 2.28b)
NOPAT = 2.78b (EBIT 3.83b * (1 - 27.52%))
Current Ratio = 1.22 (Total Current Assets 15.73b / Total Current Liabilities 12.85b)
Debt / Equity = 0.35 (Debt 10.10b / last Quarter total Stockholder Equity 28.82b)
Debt / EBITDA = 1.59 (Net Debt 9.22b / EBITDA 6.37b)
Debt / FCF = 3.74 (Debt 10.10b / FCF TTM 2.70b)
Total Stockholder Equity = 30.66b (last 4 quarters mean)
RoA = 2.64% (Net Income 1.49b, Total Assets 56.37b )
RoE = 4.86% (Net Income TTM 1.49b / Total Stockholder Equity 30.66b)
RoCE = 9.94% (Ebit 3.83b / (Equity 30.66b + L.T.Debt 7.91b))
RoIC = 8.55% (NOPAT 2.78b / Invested Capital 32.50b)
WACC = 6.58% (E(57.88b)/V(67.98b) * Re(7.54%)) + (D(10.10b)/V(67.98b) * Rd(1.45%) * (1-Tc(0.28)))
Shares Correlation 3-Years: 34.82 | Cagr: 0.0%
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 74.13% ; FCFE base≈2.93b ; Y1≈2.29b ; Y5≈1.49b
Fair Price DCF = 109.3 (DCF Value 27.78b / Shares Outstanding 254.2m; 5y FCF grow -26.02% → 3.0% )
EPS Correlation: 3.27 | EPS CAGR: -11.00% | SUE: 0.39 | # QB: 0
Revenue Correlation: 47.96 | Revenue CAGR: 6.43%